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Abstract
Background—Occupational exposure to extremely low frequency magnetic fields (ELF) is a
suspected risk factor for brain tumours, however the literature is inconsistent. Few studies have
assessed whether ELF in different time windows of exposure may be associated with specific
histologic types of brain tumours. This study examines the association between ELF and brain
tumours in the large-scale INTEROCC study.
Methods—Cases of adult primary glioma and meningioma were recruited in seven countries
(Australia, Canada, France, Germany, Israel, New Zealand, United Kingdom) between 2000 and
2004. Estimates of mean workday ELF exposure based on a job exposure matrix assigned.
Estimates of cumulative exposure, average exposure, maximum exposure, and exposure duration
were calculated for the lifetime, and 1–4, 5–9, and 10+ years prior to the diagnosis/reference date.
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Results—There were 3,761 included brain tumour cases (1,939 glioma, 1,822 meningioma) and
5,404 population controls. There was no association between lifetime cumulative ELF exposure
and glioma or meningioma risk. However, there were positive associations between cumulative
ELF 1–4 years prior to the diagnosis/reference date and glioma (odds ratio (OR) ≥ 90th percentile
vs < 25th percentile = 1.67, 95% confidence interval (CI) 1.36–2.07, p < 0.0001 linear trend), and,
somewhat weaker associations with meningioma (OR ≥ 90th percentile vs < 25th percentile = 1.23,
95% CI 0.97–1.57, p = 0.02 linear trend).
Conclusions—Results showed positive associations between ELF in the recent past and glioma.
Impact—Occupational ELF exposure may play a role in the later stages (promotion and
progression) of brain tumourigenesis.
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INTRODUCTION
There are few established risk factors for brain tumours (1). In countries with cancer
registries, it is estimated that the annual age-standardized incidence rate of primary
malignant tumours of the brain and nervous system is between three and four per 100,000. It
is slightly higher among males than females and in developed than developing countries
(1,2). Small increases in the incidence of some types of brain tumours have been observed
over recent decades, due to changes in diagnosis, classification, and coding (1,3).
Although ionizing radiation is an established risk factor for the disease, it accounts for a
small fraction of the total number of cases (4,5). Possible associations between occupational
exposure to non-ionizing radiation sources, in particular extremely low frequency magnetic
fields (ELF), which occur during the generation, distribution and use of alternating current
electricity, and brain tumours have been examined; however, results are inconsistent and
limited by small study sizes and a lack of occupational history data (6). Previous studies
have also varied widely in terms of methodology. There have been studies of highly exposed
occupational groups, including for example electrical workers, railway professionals, and
resistance welders, with study designs ranging from job title-based studies, comparing rates
of brain tumours to those expected in the general population (7–9), to studies based on
detailed measurements and modelling (10) or job exposure matrices (JEMs) (11–12). There
are also general population studies with ELF exposure assessments ranging from self-report
or expert judgment through to JEMs (13–17).
A meta-analysis of 48 studies published during 1993–2007 reported a small positive
association between occupational ELF and brain tumours overall (relative risk (RR) = 1.14,
95% confidence interval (CI) 1.07–1.22); however, there was no exposure-response
relationship using approximations of ELF exposure categories in the original papers (18).
Study characteristics that tended to be associated with stronger positive findings included a
poor quality exposure assessment, a poorly defined comparison group, as well as an
adequate study design.
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Most recently, a US study of 489 glioma cases, 197 meningioma cases, and 799 controls
reported no association between ELF and glioma (odds ratios (OR) cumulative exposure >
45 milligauss(mG)-years (1 μT = 10 mG) vs 0 exposure > 1.5 mG = 0.8, 95% CI 0.5–1.2) or
meningioma risk (OR = 1.0, 95% CI 0.6–1.8) (19). A French study of 221 cases of central
nervous system (CNS) tumours and 442 controls, reported a positive association between
ELF and meningioma (OR = 3.02, 95% CI 1.10–8.25) (17). No association between ELF
and incident brain tumours (n=233) was observed in the Netherlands Cohort Study (20) nor
in a study of UK electricity supply workers (n=266) (21).
The International Agency for Research on Cancer (IARC) classified ELF as possibly
carcinogenic to humans (Group 2B), based on studies of childhood leukemia, but with
inadequate evidence for all other cancers (22). Similar conclusions have been reached more
recently (6,23,24). Mechanistically, any role of ELF would likely manifest on the later
stages of tumour development, specifically in cancer promotion/progression as suggested by
some co-carcinogenicity studies (22,24,25). Few epidemiological studies have had sufficient
power to address this hypothesis. Results from some, but not all, studies have observed
stronger associations between ELF and brain tumours in the more recent compared to the
more distant past, or with more aggressive forms of glioma (11, 13, 16, 26–29).
This study assesses the role of occupational ELF exposure for specific histologic types of
brain tumours, namely glioma and meningioma, using data from the large-scale INTEROCC
study. Detailed lifetime occupational histories were collected, providing a unique




The INTEROCC study is based on a subset of countries from INTERPHONE, a large, 13-
country, population-based case-control study conducted according to a common protocol
(30). Cases of primary brain (glioma, meningioma), CNS (acoustic neuroma), and salivary
gland tumours, aged between 30 and 59 years were recruited between 2000 and 2004.
Although INTERPHONE’s primary objective was to examine whether radiofrequency (RF)
field exposure from cellular telephones was associated with cancer risk, seven of
INTERPHONE 13 countries, collected detailed occupational data and participated in the
subsequent INTEROCC study to address outstanding questions concerning occupational
agents in glioma and meningioma.
Incident cases were rapidly recruited (median delay from diagnosis to interview ~3 months)
from major treatment centers in areas of Australia, Canada, France, Germany, New Zealand,
the United Kingdom, and nationwide in Israel, with completeness verified through
secondary sources. An expanded age range was used for INTEROCC with Germany
including cases aged up to 69 years, the UK 18 to 69 years, and in Israel cases aged 18+
years were recruited to allow for greater case ascertainment. Cases were confirmed
histologically or through unequivocal diagnostic imaging.
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Controls were randomly selected from electoral lists (Australia, Canada-Montreal, France,
New Zealand), population-based registries (Canada-Vancouver, Germany, Israel), patient
lists (UK), or random digit dialing (Canada-Ottawa) according to study center. Controls
were either frequency- or individually-matched to cases by sex, age (five year groups) and
study center within country.
Although the original INTERPHONE protocol called for the selection of only one control
for each case of glioma or meningioma, all eligible controls were used here to maximize
statistical power. The reference date of controls was calculated as the date of interview
minus the median difference between the date of case diagnosis and interview by country.
Participants provided written informed consent prior to interview. There were 5,399 eligible
brain tumour cases (3,017 gliomas and 2,382 meningiomas) and 11,112 controls (identified
from the sampling frame) among whom 3,978 cases (2,054 gliomas and 1,924
meningiomas) and 5,601 controls were interviewed. Major reasons for non-participation
among controls in the overall INTERPHONE study include refusal (64%) and inability to
contact (27%) (30). Overall participation rates for high-grade and low-grade glioma cases
were also similar (67 vs 71% respectively) (30). Ethics approval was obtained from
appropriate national and regional research ethics boards including the Ethical Review Board
of IARC (Lyon) for INTERPHONE and the Municipal Institute for Medical Investigation
(IMIM) Barcelona for INTEROCC.
Data Collection
Eligible participants were interviewed by trained interviewers using a computer-assisted
personal interview questionnaire. If the participant had died or was unable to participate, a
proxy respondent was allowed. The questionnaire captured detailed data on a range of
personal and family characteristics. Participants also completed a lifetime occupational
calendar for all jobs held for a minimum of six months, including job title, company name,
company description, start and stop year.
Exposure Assessment
A total of 35,862 jobs were reported. A total of 599 jobs (1.7%) were excluded (assigned no
ELF exposure) due to invalid start/stop dates; and an additional 23 jobs (0.06%) excluded
that ceased prior to age 14 years. Job titles were coded to the International Standard
Classification of Occupations 1988 (ISCO88) four digit codes as well as 1968 (ISCO68) five
digit codes, since it contains codes for occupations in the utility industry. Coding guidelines
were provided to study centers and an inter-coding trial conducted to ensure consistency
(31). The mean (SD) number of jobs per subject was 3.9 (±2.6) for glioma cases, 3.6 (±2.6)
for meningioma cases, and 3.8 (±2.5) for controls. A small number of participants (103
glioma cases, 95 meningioma cases, and 122 controls) who reported having never been
employed were excluded here.
Estimates of mean workday-average ELF exposures came from an enhancement of a
measurement-based JEM (32). The JEM was linked to the ISCO88 code for each job unless
a JEM estimate was available for a more specific electrical job in ISCO68. The JEM was
substantially enhanced by including measurement data on jobs included in the INTEROCC
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study based on summary statistics or primary data from published occupational studies in
Canada, England, Finland, Italy, the Netherlands, New Zealand, Sweden, and the US. These
studies used personal monitors to measure ELF exposure reporting the full-shift time-
weighted average (TWA) “resultant” of the magnetic flux density in μT. All measurements
were made using monitors with bandwidths within a range of 3 to 1,000 Hz.
Pooling studies in the JEM, estimates of geometric mean (GM) were calculated for 278
primary ISCO codes. Where there were no measurement data for a specific ISCO code,
exposures were inferred based on similar jobs within the ISCO hierarchy (72 ISCO codes,
4.2% of the jobs of INTEROCC subjects) or estimated using expert judgement (60 ISCO
codes, 1.8% of INTEROCC jobs). Jobs classified as an unknown occupation (n=105, 0.3%
of jobs) were assigned the geometric mean of control values by centre. Supplementary Table
S1 presents a description of ELF levels in selected participant jobs. An online version of the
JEM is available at: http://www.crealradiation.com/index.php/en/databases?id=55.
Statistical Analysis
Conditional logistic regression models were used to obtain adjusted ORs and 95% CIs for
the association between occupational ELF and brain tumours in seven countries combined
stratified by region, country, sex, and five-year age group, and adjusted for education.
Categorical indicators of cumulative and average ELF exposure with cut points based on the
25th, 50th, 75th, and, due to the skewed nature of the distribution, the 90th percentile of the
control exposure distribution were examined for the lifetime (1-year lag) and in separate
exposure-time windows defined a priori, 1–4, 5–9, and 10+ years prior to the date of
diagnosis/reference date. Since ELF exposure is ubiquitous, the reference group consisted of
participants in the lowest exposure category. Since the most relevant ELF metric, if any, is
unknown (19), indicators of maximum exposed job and duration of employment in a job in
the highest quartile of participant jobs (>= 0.18 μT) were also examined.
Potential confounding by marital status, cigarette smoking, socioeconomic position
(Standard International Occupational Prestige Scale (SIOPS)) (33), allergy history,
occupational ionizing radiation (reported wearing a radiation badge), occupational cosmic
radiation (prior flight-related occupation), and cumulative cellular telephone use (deciles of
minutes of call time for Australia, Canada, France, Israel, New Zealand) were examined but
produced virtually no change (<10%) in ORs (not presented) (34, 35, 36). Potential
confounding by ever exposure to 29 occupational chemicals selected a priori was also
examined, based on chemical exposure estimates assigned based on a modified version of
the Finnish job exposure matrix (FINJEM) to study participants as part of INTEROCC (37).
Sensitivity analyses were conducted excluding proxy interviews (30), participants who were
judged by the interviewer to be reticent and uninterested in the interview and, participants >
69 years of age, participants with a history of self-reported physician-diagnosed
neurofibromatosis or tuberous sclerosis, and for low and high-grade glioma separately.
Potential effect modification by country, age, sex, and education was assessed by entering
product terms into conditional logistic regression models and assessing their significance
according to the likelihood ratio test. Analyses were conducted using SAS version 9.3 (38).
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A total of 1,939 (94.4%) glioma cases, 1,822 (94.7%) meningioma cases and 5,404 (96.5%)
controls were retained for analysis. The majority of glioma cases were male (62.0%), with
meningioma cases being predominantly female (72.5%) (Table 1). The mean (SD) age of
study participants was 51.0 (±12.3) years for glioma cases, 54.7 (±11.6) years for
meningioma cases, and 51.8 (±11.3) years for controls. The majority of participants had at
least a high school education. Levels of lifetime cumulative ELF exposure ranged from
0.02–0.05 μT-years to 467.83–715.93 μT-years in cases (glioma/meningioma) and 0.03 μT-
years to 609.38 μT-years in controls (Supplementary Table S2).
For glioma, there was no association with lifetime cumulative exposure, average exposure,
maximum exposed job, or duration of exposure, and there was no exposure-response
relationship (Table 2). However, for cumulative ELF there were positive associations in the
1–4 year time window prior to tumour diagnosis/reference date, with ORs ranging from 1.19
(95% CI 1.00–1.43) to 1.67 (95% CI 1.36–2.07) in the highest exposure category (≥ 90th
percentile) (p linear trend < 0.0001) (Table 3), comprising ~76% of participants in that time
window, relative to those < 25th percentile. There were weaker positive associations in the
5–9 year time window. In the 10+ year time window, there was a weak, non-monotonic
inverse association with increasing ELF exposure (OR ≥ 90th percentile vs < 25th percentile
= 0.77, 95% CI 0.60–0.99, p linear trend = 0.04). ORs (95% CIs) from a simultaneous
exposure time windows model, including cumulative ELF from all three exposure time
windows together in the same model, are presented in Figure 1a. Strong correlations
between levels of cumulative ELF were observed for glioma cases and controls in the 1–4
and 5–9 year time windows (Supplementary Table S3), but were weaker for other time
windows. Results were similar for both high- and low-grade glioma (Supplementary Table
S4). Results for average exposure were generally similar in the 5–9 and 10+ year time
windows, but in the 1–4 year time window, the positive association was attenuated
(Supplementary Table S5). For maximum exposed job, there was a significant inverse trend
(p = 0.003) in the 10+ year time window (Supplementary Table S6).
For meningioma, there was no association with lifetime cumulative exposure, average
exposure, or maximum exposed job (Table 2). However, there was an elevated OR in the
highest exposure duration group (25+ vs < 5 years) (OR = 1.30, 95% CI 1.03–1.64). There
was also a significant positive linear trend (p = 0.02) with cumulative ELF exposure 1–4
years prior to tumour diagnosis/reference date (Table 3). No associations were seen in the 5–
9 or 10+ year time windows. Figure 1b presents ORs (95% CIs) from a simultaneous
exposure time windows model. For maximum exposed job, there was a significant positive
trend (p = 0.03) in the 1–4 year time window (Supplementary Table S6).
Results for glioma with cumulative ELF in the 1–4 year time window were virtually
unchanged with adjustment for occupational chemical exposures, with the exception of
adjustment for benzo(a)pyrene (BAP) or polycyclic aromatic hydrocarbon (PAH) exposures,
where ORs increased in the highest ELF exposure categories (Supplementary Table S7).
ORs in some categories increased for both glioma and meningioma when excluding
participants who were judged by the interviewer to be reticent and uninterested in the
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interview for cumulative ELF in the 1–4 year time window, however in the 10+ year time
window, the weak inverse trend attenuated (Table 4). There was no significant effect
modification observed.
DISCUSSION
Results from this large-scale study revealed no association between lifetime occupational
exposure to ELF, but positive associations with cumulative ELF 1–4 years prior to the
diagnosis/reference date and glioma. Weaker positive associations were observed for
meningioma. There was also a weak inverse association for glioma with ELF exposure in
the distant past (10+ year time window), which attenuated when subjects judged to be
reticent and unresponsive were excluded from analyses.
Some studies reported stronger associations with occupational ELF in more recent exposure
time windows. Among general population studies, Villeneuve et al. (16), in a study of 543
incident brain tumour cases and controls, observed positive associations in the highest
category of average ELF exposure (≥0.6 μT vs < 0.3 μT) for all brain tumours (OR = 1.33,
95% CI 0.75–2.36) and glioblastoma multiforme (OR = 5.36, 95% CI 1.16–24.78) which
strengthened for ELF in the last held job (OR = 12.59, 95% CI 1.50–105.6, number of cases
(controls) = 18 (6)). Floderus et al. (13), in a study of 261 brain tumour cases and 1,112
controls noted positive associations between ELF in the longest job 10 years prior to
diagnosis.
Among more highly exposed occupational groups, previous results were mixed, however,
there were small numbers of cases and few examined associations in different time windows
(10). Savitz et al. (27), in a case-cohort study including 145 brain tumour deaths from five
US electric utility companies, reported positive associations with cumulative ELF (OR =
1.79, 95% CI 0.69–4.65 highest exposed group, 4.33–12.20 vs 0–0.65 μT-years) that
strengthened 2–10 years in the past (OR highest exposed group, 1.14–2.23 vs 0 μT-years =
2.62, 95% CI 1.15–5.97). Hakansson et al. (11) in a cohort of over 700,000 resistance
welders, observed positive associations between average ELF and astrocytoma in women (n
= 66, p for trend = 0.004) in 10 years of follow-up. However, this was not observed in other
studies (21, 28, 29).
Although ELF exposure in the 1–4 year time window represents a small proportion of total
lifetime occupational ELF exposure, these results are compatible with a role in tumour
promotion. ELF cannot impart enough energy to DNA molecules to create mutations,
however, it may act on signal transduction, cell proliferation, reactive oxygen species
generation, the neuroendocrine or immune system, or interact with other chemical exposures
(24, 25). Villeneuve et al. (16) suggested that stronger associations observed with more
aggressive forms of glioma may also provide support for a promotional role of ELF,
however similar findings were observed for both high- and low-grade glioma here. There
was also a weak positive association between ELF in the longest exposure duration category
and meningioma (and possibly glioma), possibly suggesting a role for prolonged ELF
exposure for that slower growing tumour. Alternatively, findings in different time windows
of exposures may be due to chance.
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Potential limitations include low participation rates, particularly among controls (ranging
from 35–74%) (30). The Swedish INTERPHONE study noted participation was positively
associated with working status, income, and education (39). However education was similar
for participating cases and controls here. Cases and controls reported a similar number of
lifetime jobs. Mean (SD) weighted indicators of occupational prestige (SIOPS) were similar
(glioma = 43.0 (±11.7), meningioma = 42.2 (±12.4), controls = 43.8 (±12.0)).
The positive association between ELF and glioma in the 1–4 year time window was seen for
all exposure categories, including a large majority (~76%) of participants, across a wide
spectrum of occupations, not solely “electrical occupations”. Although preclinical symptoms
of a brain tumour might lead to earlier diagnosis in certain jobs; they might also influence
changes in occupation in different time windows, particularly for low grade glioma. The
mean (SD) difference between average ELF levels in the 10+ and 1–4 year time windows
was 0.001 (±0.58) for glioma cases and 0.02 (±0.31) for controls, indicating slight increases
in ELF in more recent years. The pre-clinical phase of brain tumours is poorly understood.
Fewer participants reported working in a job in the 1–4 year time window; however this
appears to be unrelated to case/control status with 84% and 82% of included glioma cases
and controls respectively reporting a job in this time window. The association with glioma
remained, though attenuated slightly, upon restriction to participants who worked for a full
four years in the 1–4 year time window (OR ≥ 90th percentile vs < 25th percentile = 1.44,
95% CI 1.02–2.05, p = 0.05 linear trend).
We also excluded a small number (n=320) of participants who reported having never been
employed from analysis in an attempt to avoid potential selection bias by socioeconomic
and/or employment status in analysis (5% of glioma cases, 5% of meningioma cases, and
2% of controls). Results including never employed participants in the reference category
attenuated somewhat for glioma for ELF in the 1–4 year time window (OR ≥ 90% vs < 25 %
= 1.45, 95% CI 1.20, 1.76) but the positive linear trend remained (p < 0.0001). For
meningioma, the weak positive trend for ELF in the 1–4 year time window disappeared (OR
≥ 90% vs < 25 % = 1.07, 95% CI 0.86, 1.34) and was no longer significant (p = 0.28).
The weak inverse association between ELF in the 10+ year time window and glioma
attenuating when subjects judged to be reticent and unresponsive were excluded from
analyses may reflect some form of reporting bias among these subjects. Reticence and
unresponsiveness was based solely on the personal opinion of the 130 interviewers in
INTEROCC study countries.
Limitations of using a JEM include exposure misclassification, although it is likely non-
differential. A US study modified JEM values based on time and distance information for
ELF sources for 24% of jobs (19). This increased the ELF exposure category for 27% of
jobs and decreased it for 15% of jobs. The modification also did not include the magnitude
of a source’s ELF emissions, which may introduce further misclassification. The
representativeness of the JEM across different countries and time periods is also unclear.
Although here we relied on the overall JEM estimates, in sensitivity analyses using country-
specific estimates where they were available in the JEM, as well as sex and time-period
specific estimates, results were virtually identical to those obtained here. This study’s focus
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on the TWA of the ELF magnetic field resultant also neglects other potentially important
aspects of electromagnetic environment such as the magnetic field frequency spectrum, its
polarization, intermittency, electric fields, shocks, contact currents, and neighboring bands
of the EM spectrum. There is little evidence for a role of ELF electric fields in
carcinogenesis (40).
In conclusion, in this large-scale study we observed no association with lifetime
occupational ELF exposure. However, results from this, and several smaller previous studies
showed positive associations between ELF in the more recent past and glioma, and probably
with meningioma. Future work to better understand possible biological mechanims of
action, interactions with other occupational exposures, associations with other occupational
EMF exposures including intermediate and RFs, and to consider inter-individual variation in
ELF exposure is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1a. Adjusted ORs (95% CIs) for glioma in relation to categories of cumulative
occupational ELF-MF exposure in the 1–4, 5–9, and 10+ year time windows prior to the
date of diagnosis/reference date from a simultaneous exposure time windows model with
cutpoints based on the 25th, 50th, 75th, and 90th percentile, INTEROCC study, 2000–2004,
Australia, Canada, France, Germany, Israel, New Zealand, and United Kingdom
Figure 1b. Adjusted ORs (95% CIs) for meningioma in relation to categories of cumulative
occupational ELF-MF exposure in the 1–4, 5–9, and 10+ year time windows prior to the
date of diagnosis/reference date from a simultaneous exposure time windows model with
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cutpoints based on the 25th, 50th, 75th, and 90th percentile, INTEROCC study, 2000–2004,
Australia, Canada, France, Germany, Israel, New Zealand, and United Kingdom
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Table 1
Characteristics of case and control participants at enrollment INTEROCC study, 2000–2004, Australia,
Canada, France, Germany, Israel, New Zealand, and United Kingdom
Glioma Cases (n=1,939) Meningioma Cases (n=1,822) Controlsa (n=5,404)
% % %
Sex
 Male 62.0 27.5 45.2
 Female 38.0 72.5 54.8
Age at reference date
 <35 11.0 4.4 7.3
 35–39 9.3 5.4 8.7
 40–44 11.1 9.2 11.6
 45–49 12.3 14.8 13.8
 50–54 18.0 20.4 18.3
 55–59 16.1 17.1 18.7
 60–64 9.9 10.3 9.2
 65–69 6.8 8.7 7.9
 70+ 5.6 9.8 4.4
Education
 High School or less 52.4 59.1 53.6
 Medium level technical school 19.7 19.5 19.0
 University 28.0 21.4 27.4
Country
 Australia 14.2 13.9 12.3
 Canada 8.6 5.1 11.6
 France 4.8 7.6 8.5
 Germany 18.6 20.3 27.5
 Israel 20.5 36.8 17.3
 New Zealand 3.4 2.7 2.7
 United Kingdom 30.0 13.5 20.1
a
Glioma and meningioma controls combined.
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